Active substance
Vitamin b12
- Health Canada 4
- Safety 1
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| CYANOCOBALAMIN INJECTION USP | 01987003 | 1000 MCG / ML | SOLUTION · SUBCUTANEOUS; INTRAMUSCULAR | STERIMAX INC |
| CYANOCOBALAMIN INJECTION USP | 02463393 | 1000 MCG / ML | SOLUTION · SUBCUTANEOUS; INTRAMUSCULAR | HIKMA CANADA LIMITED |
| CYANOCOBALAMIN INJECTION USP | 02465507 | 1000 MCG / ML | SOLUTION · INTRAMUSCULAR; SUBCUTANEOUS | HIKMA CANADA LIMITED |
| VITAMIN B12 | 00521515 | 1000 MCG / ML | SOLUTION · SUBCUTANEOUS; INTRAMUSCULAR | SANDOZ CANADA INCORPORATED |
Safety signals and safety-related labeling changes
- MHRA 18 Dec 2023 Vitamin B12 (hydroxocobalamin, cyanocobalamin): advise patients with known cobalt allergy to be vigilant for sensitivity reactions
The medicines used to treat vitamin B12 deficiency (hydroxocobalamin, cyanocobalamin) contain cobalt. There are case reports in the literature describing cobalt sensitivity-type reactions in patients being treated for vitamin B12 deficiency.
Combinations containing Vitamin b12
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.